Australia markets closed

Evaxion Biotech A/S (EVAX)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
3.7200-0.0200 (-0.53%)
At close: 04:00PM EDT
4.0000 +0.28 (+7.53%)
After hours: 07:20PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 20.13M
Enterprise value 25.42M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)139.30
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.73

Trading information

Stock price history

Beta (5Y monthly) -0.21
52-week change 3-76.31%
S&P500 52-week change 326.27%
52-week high 318.5000
52-week low 32.8240
50-day moving average 33.6074
200-day moving average 36.6792

Share statistics

Avg vol (3-month) 349.67k
Avg vol (10-day) 311.49k
Shares outstanding 55.41M
Implied shares outstanding 637.91M
Float 836.71M
% held by insiders 116.60%
% held by institutions 10.91%
Shares short (30 Apr 2024) 453.21k
Short ratio (30 Apr 2024) 41.08
Short % of float (30 Apr 2024) 41.40%
Short % of shares outstanding (30 Apr 2024) 40.98%
Shares short (prior month 28 Mar 2024) 442.58k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:10
Last split date 322 Jan 2024

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-5,978.08%

Management effectiveness

Return on assets (ttm)-79.47%
Return on equity (ttm)-1,238.11%

Income statement

Revenue (ttm)73k
Revenue per share (ttm)0.03
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -21.8M
Net income avi to common (ttm)-22.12M
Diluted EPS (ttm)-8.1000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)5.58M
Total cash per share (mrq)0.11
Total debt (mrq)10.87M
Total debt/equity (mrq)N/A
Current ratio (mrq)1.18
Book value per share (mrq)-1.25

Cash flow statement

Operating cash flow (ttm)-17.69M
Levered free cash flow (ttm)-9.12M